Drug/Small Molecule:
aspirin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with aspirin that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105072

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available CA No VIP available G6PD B (wildtype) N/A N/A N/A
No VIP available CA VA G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham N/A N/A N/A
No VIP available No Clinical Annotations available VA
G6PD deficiency N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10279545 101171028T>C, 380-5335T>C, 39203871T>C
T > C
Intronic
No VIP available CA VA
rs10306114 -1140A>G, -287A>G, -762A>G, -842A>G, -890A>G, -920A>G, 125132522A>G, 4294A>G, 54297054A>G, A-842G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs1050450 *581C>T, 49334834G>A, 49394834G>A, 5958C>T, 599C>T
G > A
Missense
Pro200Leu
No VIP available CA VA
rs1050891 *60A>G, 138771760A>G, 28520423A>G, 54953A>G
A > G
3' UTR
No VIP available No Clinical Annotations available VA
rs1057910 1075A>C, 47545517A>C, 47639A>C, 96741053A>C, CYP2C9*3, CYP2C9*3:Ile359Leu, CYP2C9: I359L, CYP2C9:359Ile>Leu, CYP2C9:Ile359Leu, Ile359Leu, mRNA 11A>C
A > C
Missense
Ile359Leu
No VIP available No Clinical Annotations available VA
rs1059288 *1865T>C, -1067T>C, -1116T>C, 19318T>C, 33207672A>G, 33267672A>G, 4499912G>G, 4548998G>G, 4711486G>G, 4741416A>G
G > A
3' UTR
No VIP available CA VA
rs1062535 2945772G>A, 52351413G>A, 71258G>A, 825G>A, 847G>A, 968G>A, Thr275=
G > A
Not Available
Thr275Thr
No VIP available CA VA
rs1065776 152553628C>T, 57C>T, 5893C>T, 59048774C>T, Ala19=, P2RY1:893C>T, P2RY1:C893T
C > T
Synonymous
Ala19Ala
No VIP available No Clinical Annotations available VA
rs11188072 -3402, 1599C>T, 47323525C>T, 96519061C>T, CYP2C19:, CYP2C19: -3402C>T, part of CYP2C19*17
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1126510 *754T>C, 19392001A>G, 47123783A>G
A > G
3' UTR
No VIP available CA VA
rs1126643 2941728C>T, 52347369C>T, 67214C>T, 759C>T, 781C>T, 902C>T, GPIa 807C >T, Phe253=
C > T
Not Available
Phe253Phe
No VIP available CA VA
rs1131882 15909C>T, 3535923G>A, 3595923G>A, 795C>T, Ile265=
G > A
Synonymous
Ile265Ile
No VIP available CA VA
rs1143627 -118C>T, 113594387G>A, 3343050G>A, 4970C>T
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs11558538 138759649C>T, 28508312C>T, 314C>T, 42842C>T
C > T
Missense
Thr105Ile
No VIP available CA VA
rs11587213 -237A>G, 12673517A>G, 161184875A>G, 20771A>G, 4789A>G
A > G
5' Flanking
No VIP available CA VA
rs12041331 -9-3996G>A, 156869714G>A, 8358356G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs12042763 186651876G>T, 2684C>A, 38140518G>T
G > T
Not Available
No VIP available No Clinical Annotations available VA
rs12248560 -806C>A, -806C>T, 4195C>A, 4195C>T, 47326121C>A, 47326121C>T, 96521657C>A, 96521657C>T, CYP2C19*17, CYP2C19*17 CYP2C19: -806C>T, CYP2C19: -806C>T
C > T
C > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs1236913 -276T>C, -277T>C, -306T>C, 102T>C, 125133479T>C, 22T>C, 328T>C, 5251T>C, 54298011T>C, C22T, Trp8Arg
T > C
5' UTR
Trp8Arg
No VIP available No Clinical Annotations available VA
rs13233066 101088697G>A, 282-2274G>A, 39121540G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs1353411 -166G>A, 33781101G>A, 5086G>A, 52781101G>A
G > A
5' UTR
No VIP available CA VA
rs1613662 1005212G>A, 1007298G>A, 1032749G>A, 18038C>T, 27804813G>A, 55536595G>A, 610+2351C>T, 655C>T, 670428G>A, 737387G>A, 928009G>A, 928625G>A, 943591G>A, C13254T, Pro219Ser
G > A
Intronic
Pro219Ser
No VIP available CA VA
rs16851030 *424C>T, 203135452C>T, 54624094C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs17470799 101175099G>A, 380-1264G>A, 39207942G>A
G > A
Intronic
No VIP available CA VA
rs1799983 11291734T>G, 12965T>G, 150696111T>G, 894T>G, Asp298Glu, NOS3:894G>T
T > G
Missense
Asp298Glu
No VIP available No Clinical Annotations available VA
rs1800469 *309T>C, -1347T>C, 1347 C>T, 14128514A>G, 14783T>C, 41860296A>G, 4536T>C, 509 C>T, TGFB1:
A > G
3' Flanking
rs20417 -899G>C, 186650321C>G, 38138963C>G, 4239G>C, COX-2 G-765C, PTGS2:-765G>C
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2071888 14135C>G, 33212855G>C, 33272855G>C, 4505105C>C, 4554190C>C, 4716678C>C, 4746599G>C, 518C>G, 779C>G, Thr173Arg, Thr260Arg
C > G
Missense
Thr173Arg
No VIP available No Clinical Annotations available VA
rs2075797 -616C>G, 33780651C>G, 4636C>G, 52780651C>G
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2108622 1297G>A, 14389G>A, 15990431C>T, 23454G>A, 7253233C>T, CYP4F2 exon 11, CYP4F2: C>T, CYP4F2: V433M, CYP4F2:V433M, V433M, Val433Met, c.1297G>A, mRNA 1347G>A, p.Val433Met
C > T
Missense
Val433Met
No VIP available CA VA
rs2228079 203098275T>G, 306T>G, 54586917T>G, Ala102=
T > G
Synonymous
Ala102Ala
No VIP available No Clinical Annotations available VA
rs2243093 -5 C/T, -5T>C, 4439269T>C, 4835895T>C, 5306T>C
T > C
5' UTR
No VIP available CA VA
rs2243250 -589C>T, 132009154C>T, 40323026C>T, 4782C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs2427827 -59-285T>C, 10760453T>C, 159271811T>C
T > C
Intronic
No VIP available CA VA
rs2768759 156852463A>C, 71922A>C, 8341105A>C
A > C
Not Available
No VIP available No Clinical Annotations available VA
rs3775291 111551795C>T, 1234C>T, 187004074C>T, 18766C>T, Leu412Phe, TLR3: L412F, TLR3: P412L
C > T
Missense
Leu412Phe
No VIP available No Clinical Annotations available VA
rs3798220 131271A>G, 160961137T>C, 5673A>G, 65130594T>C, Ile1891Met
T > C
Missense
Ile1891Met
No VIP available No Clinical Annotations available VA
rs3842787 -248C>T, -249C>T, -278C>T, 125133507C>T, 130C>T, 356C>T, 50C>T, 5279C>T, 54298039C>T, C>T, PTGS1: P17L, Pro17Leu
C > T
5' UTR
Pro17Leu
No VIP available CA VA
rs3856806 12415557C>T, 12475557C>T, 1347C>T, 1431C>T, 151209C>T
C > T
Synonymous
His449His
No VIP available No Clinical Annotations available VA
rs4244285 24154G>A, 24154G>C, 47346080G>A, 47346080G>C, 681G>A, 681G>C, 96541616G>A, 96541616G>C, CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, Pro227=
G > C
G > A
Synonymous
Pro227Pro
rs4271002 -594G>C, 18248268G>C, 4514G>C, 6106414G>C, NAT2 -594G>C, NAT2(-9246)C>G
G > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs4291 -262T>A, 26828346T>A, 4761T>A, 61554194T>A
T > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs4292 -115C>T, 26828493C>T, 4908C>T, 61554341C>T
C > T
5' Flanking
No VIP available CA VA
rs4523 16038T>C, 3535794A>G, 3595794A>G, 924T>C, Tyr308=
A > G
Synonymous
Tyr308Tyr
No VIP available No Clinical Annotations available VA
rs4727494 101081798G>A, 282-9173G>A, 39114641G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs499368 -422+272A>T, -57-1711A>T, -58+272A>T, 260920T>A, 320920T>A
T > A
T > C
Intronic
VIP No Clinical Annotations available No Variant Annotations available
rs5030868 153762634G>A, 18154C>T, 4680572G>A, 563C>T, 653C>T, Mediterranean, Ser188Phe, Ser218Phe
G > A
Not Available
Ser218Phe
No VIP available No Clinical Annotations available VA
rs5050 -58A>C, 230849886T>G, 24367665T>G, 5451A>C
T > G
5' UTR
No VIP available No Clinical Annotations available VA
rs557881 259125A>G, 28T>C, 319125A>G, Cys10Arg
A > G
Missense
Cys10Arg
No VIP available No Clinical Annotations available VA
rs5788 1167C>A, 125143792C>A, 15564C>A, 312C>A, 495C>A, 54308324C>A, 564C>A, 639C>A, 690C>A, C644A, Gly104=, Gly165=, Gly188=, Gly213=
C > A
Synonymous
Gly188Gly
No VIP available No Clinical Annotations available VA
rs5789 1237C>A, 125143973C>A, 15745C>A, 382C>A, 54308505C>A, 565C>A, 634C>A, 709C>A, 760C>A, C714A, Leu128Met, Leu189Met, Leu212Met, Leu237Met
C > A
Missense
Leu212Met
No VIP available CA VA
rs5918 10634882T>C, 176T>C, 34523T>C, 45360730T>C, A2, GP IIIa HPA-1, GP3A PIA2, HPA-1b, ITGB3:1565T>C, ITGB3:Leu33Pro, Leu33Pro polymorphism of ß3 integrins, Leu59Pro, P1A2, PI, PIA1/PIA2
T > C
Missense
Leu59Pro
No VIP available CA VA
rs5985 103G>T, 6258795C>A, 6318795C>A, 7130G>T, Val35Leu
C > A
Missense
Val35Leu
No VIP available CA VA
rs6065 4439755C>T, 482C>T, 4836381C>T, 5792C>T, GP1BA 145Thr/Met, Thr161Met
C > T
Missense
Thr161Met
No VIP available No Clinical Annotations available VA
rs662 21439A>G, 32970289T>C, 575A>G, 94937446T>C, Gln192Arg
T > C
Missense
Gln192Arg
No VIP available No Clinical Annotations available VA
rs6785930 151056616G>A, 18C>T, 2146-11231G>A, 256941G>A, 50929C>T, 57551762G>A, Asn6=
G > A
Synonymous
Asn6Asn
No VIP available No Clinical Annotations available VA
rs6809699 151056598A>C, 2146-11249A>C, 256923A>C, 36T>G, 50947T>G, 57551744A>C, Gly12=
A > C
Synonymous
Gly12Gly
No VIP available No Clinical Annotations available VA
rs6949799 101067526C>T, 281+4146C>T, 39100369C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs6962291 1137+9085T>A, 1275+9085T>A, 139671117T>A, 1401+9085T>A, 197937T>A, 266740T>A, 933+9085T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs701265 152554357A>G, 59049503A>G, 6622A>G, 786A>G, P2RY1:1622A>G, P2RY1:1622AG, P2RY1:A1622G, Val262=
A > G
Synonymous
Val262Val
No VIP available CA VA
rs7179742 10853610A>G, 127-242T>C, 40063053A>G
A > G
Intronic
No VIP available CA VA
rs730012 -444A>C, 179220638A>C, 24031911A>C, 4653A>C, LTC4S, LTC4S: A-444C, LTC4S:-444C, rs730012
A > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs7543182 *24-21431G>T, 1078-21431G>T, 1105-21431G>T, 1309-4971G>T, 1336-4971G>T, 1336-8457G>T, 178519G>T, 41311891C>A, 71339973C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs7551789 -1478T>A, -1709T>A, 1259+298A>T, 3523T>A, 41486887A>T, 71514969A>T
A > T
5' Flanking
No VIP available CA VA
rs7572857 220G>A, 44118685G>A, 65296798G>A, Gly74Ser
G > A
Missense
Gly74Ser
No VIP available No Clinical Annotations available VA
rs8069732 10627087C>T, 165+1065C>T, 26728C>T, 45352935C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs959 *261A>G, *305A>G, 1759A>G, 1786A>G, 1855A>G, 200231A>G, 41290179T>C, 71318261T>C
T > C
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • 2-Acetoxybenzenecarboxylic acid
  • 2-Acetoxybenzoic acid
  • 2-Carboxyphenyl acetate
  • A.S.A.
  • ASA
  • Acetilsalicilico
  • Acetilum acidulatum
  • Acetosalic acid
  • Acetoxybenzoic acid
  • Acetylsalicylate
  • Acetylsalicylic acid
  • Acetylsalicylsaure (GERMAN)
  • Acetysalicylic acid
  • Acide acetylsalicylique (FRENCH)
  • Acido O-acetil-benzoico
  • Acido acetilsalicilico
  • Acidum acetylsalicylicum
  • Kyselina 2-acetoxybenzoova
  • Kyselina acetylsalicylova
  • O-Acetylsalicylic acid
  • O-accetylsalicylic acid
  • Salicylic acid acetate
  • Salicylic acid, acetate
  • o-Acetoxybenzoic acid
  • o-Carboxyphenyl acetate
Trade Names
  • 8-hour Bayer
  • A.S.A. Empirin
  • Acenterine
  • Acesal
  • Acetal
  • Aceticyl
  • Acetisal
  • Acetol
  • Acetonyl
  • Acetophen
  • Acetosal
  • Acetosalin
  • Acetylin
  • Acetylsal
  • Acimetten
  • Acisal
  • Acylpyrin
  • Adiro
  • Asagran
  • Asatard
  • Ascoden-30
  • Aspalon
  • Aspec
  • Aspergum
  • Aspirdrops
  • Aspirin
  • Aspirine
  • Aspro
  • Asteric
  • Bayer Extra Strength Aspirin For Migraine Pain
  • Benaspir
  • Bi-prin
  • Bialpirina
  • Bialpirinia
  • Bufferin
  • Caprin
  • Cemirit
  • Claradin
  • Clariprin
  • Colfarit
  • Contrheuma retard
  • Coricidin
  • Crystar
  • Decaten
  • Delgesic
  • Dolean pH 8
  • Duramax
  • ECM
  • Easprin
  • Ecolen
  • Ecotrin
  • Empirin
  • Endydol
  • Entericin
  • Enterophen
  • Enterosarein
  • Enterosarine
  • Entrophen
  • Extren
  • Globentyl
  • Globoid
  • Helicon
  • Idragin
  • Levius
  • Measurin
  • Micristin
  • Neuronika
  • Novid
  • Nu-seals
  • Nu-seals aspirin
  • Persistin
  • Pharmacin
  • Pirseal
  • Polopiryna
  • Premaspin
  • Rheumintabletten
  • Rhodine
  • Rhonal
  • Salacetin
  • Salcetogen
  • Saletin
  • Solfrin
  • Solprin
  • Solprin acid
  • Solpyron
  • Spira-Dine
  • St. Joseph
  • St. Joseph Aspirin for Adults
  • Supac
  • Tasprin
  • Temperal
  • Triaminicin
  • Triple-sal
  • Vanquish
  • Xaxa
  • Yasta
Brand Mixture Names
  • Aspirin Plus Stomach Guard (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Aspirin Plus Stomach Guard Ext.Stgth.Caplet (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Aspirin Plus Stomach Guard Extra Strength (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Aspirin Plus Stomach Guard Tab (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Aspirin with Stomach Guard (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Aspirin with Stomach Guard Extra Strength - Tab (Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide)
  • Extra Strength Aspirin Backache (Acetylsalicylic Acid + Methocarbamol)

PharmGKB Accession Id:
PA448497

Description

The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Source: Drug Bank

Indication

For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The analgesic, antipyretic, and anti-inflammatory effects of acetylsalicylic acid are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Acetylsalicylic acid directly and irreversibly inhibits the activity of both types of cyclooxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes acetylsalicylic acid different from other NSAIDS (such as diclofenac and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Acetylsalicylic acid's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation-inhibiting effect of acetylsalicylic acid specifically involves the compound's ability to act as an acetyl donor to cyclooxygenase; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Irreversible acetylation renders cyclooxygenase inactive, thereby preventing the formation of the aggregating agent thromboxane A2 in platelets. Since platelets lack the ability to synthesize new proteins, the effects persist for the life of the exposed platelets (7-10 days). Acetylsalicylic acid may also inhibit production of the platelet aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel endothelial cells; however, inhibition prostacyclin production is not permanent as endothelial cells can produce more cyclooxygenase to replace the non-functional enzyme.

Source: Drug Bank

Pharmacology

Acetylsalicylic acid is an analgesic, antipyretic, antirheumatic, and anti-inflammatory agent. Acetylsalicylic acid's mode of action as an antiinflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. Acetylsalicylic acid appears to produce analgesia by virtue of both a peripheral and CNS effect. Peripherally, acetylsalicylic acid acts by inhibiting the synthesis and release of prostaglandins. Acting centrally, it would appear to produce analgesia at a hypothalamic site in the brain, although the mode of action is not known. Acetylsalicylic acid also acts on the hypothalamus to produce antipyresis; heat dissipation is increased as a result of vasodilation and increased peripheral blood flow. Acetylsalicylic acid's antipyretic activity may also be related to inhibition of synthesis and release of prostaglandins.

Source: Drug Bank

Food Interaction

Avoid alcohol, alcohol appears to cause a 50 to 100% increases in ASA serum levels.|Take with food to reduce gastric irritation.|Take with a full glass of water.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Acetylsalicylic acid is rapidly hydrolyzed primarily in the liver to salicylic acid, which is conjugated with glycine (forming salicyluric acid) and glucuronic acid and excreted largely in the urine.

Source: Drug Bank

Protein Binding

High (99.5%) to albumin. Decreases as plasma salicylate concentration increases, with reduced plasma albumin concentration or renal dysfunction, and during pregnancy.

Source: Drug Bank

Absorption

Absorption is generally rapid and complete following oral administration but may vary according to specific salicylate used, dosage form, and other factors such as tablet dissolution rate and gastric or intraluminal pH.

Source: Drug Bank

Half-Life

The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.

Source: Drug Bank

Toxicity

Oral, mouse: LD 50 = 250 mg/kg; Oral, rabbit: LD 50 = 1010 mg/kg; Oral, rat: LD 50 = 200 mg/kg. Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia, hypotension, hallucination, renal failure, confusion, seizure, coma, and death.

Source: Drug Bank

Chemical Properties

Chemical Formula

C9H8O4

Source: Drug Bank

Isomeric SMILES

CC(=O)Oc1ccccc1C(=O)O

Source: OpenEye

Canonical SMILES

CC(=O)OC1=CC=CC=C1C(O)=O

Source: Drug Bank

Average Molecular Weight

180.1574

Source: Drug Bank

Monoisotopic Molecular Weight

180.042258744

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.

External Pathways

Links to non-PharmGKB pathways.

  1. aspirin blocks signaling pathway involved in platelet activation - (BioCarta via Pathway Interaction Database)

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
AKR1C1 (source: Drug Bank)
PTGS1 (source: Drug Bank)
PTGS2 (source: Drug Bank)

Drug Interactions

Drug Description
aspirin The salicylate at high dose increases the effect of the carbonic anhydrase inhibitors (source: Drug Bank)
acenocoumarol The salicylate increases the effect of anticoagulant (source: Drug Bank)
acenocoumarol Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol. (source: Drug Bank)
acetazolamide The salicylate at high dose increases the effect of the carbonic anyhydrase (source: Drug Bank)
acetazolamide Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide. (source: Drug Bank)
acetohexamide Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide. (source: Drug Bank)
anisindione Acetylsalicylic acid increases effect of the anticoagulant, anisindione. (source: Drug Bank)
betamethasone The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
chlorpropamide The salicylate increases the effect of sulfonylurea (source: Drug Bank)
chlorpropamide Acetylsalicylic acid increases the effect of sulfonylurea, chlorpropamide. (source: Drug Bank)
cortisone acetate The corticosteroid decreases the effect of salicylates (source: Drug Bank)
dexamethasone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
dexamethasone The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
dichlorphenamide Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide. (source: Drug Bank)
dicumarol The salicylate increases effect of anticoagulant (source: Drug Bank)
dicumarol Acetylsalicylic acid increases effect of the anticoagulant, dicumarol. (source: Drug Bank)
fludrocortisone The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
ginkgo biloba Association of ASA/ginkgo increases risk of bleeding (source: Drug Bank)
glibenclamide The salicylate increases the effect of sulfonylurea (source: Drug Bank)
glibenclamide Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide. (source: Drug Bank)
gliclazide The salicylate increases the effect of sulfonylurea (source: Drug Bank)
gliclazide Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide. (source: Drug Bank)
glipizide The salicylate increases the effect of sulfonylurea (source: Drug Bank)
glipizide Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide. (source: Drug Bank)
glisoxepide Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide. (source: Drug Bank)
glycodiazine Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine. (source: Drug Bank)
griseofulvin Anticipate decrease of ASA efficiency in presence of griseofulvin (source: Drug Bank)
griseofulvin Griseofulvin may decrease the efficacy of acetylsalicylic acid. (source: Drug Bank)
heparin Association of ASA/heparin increases risk of bleeding (source: Drug Bank)
heparin Increased risk of bleeding. (source: Drug Bank)
hydrocortisone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
hydrocortisone The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
ibuprofen Ibuprofen reduces ASA cardioprotective effects (source: Drug Bank)
ibuprofen Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended. (source: Drug Bank)
insulin-glargine The salicylate increases the effect of insulin (source: Drug Bank)
ketorolac ASA increases toxicity of ketorolac (source: Drug Bank)
ketorolac Acetylsalicylic acid may increase the adverse GI effects ketorolac. (source: Drug Bank)
methazolamide The salicylate at high dose increases the effect of the carbonic anhydrase inhibitors (source: Drug Bank)
methazolamide Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide. (source: Drug Bank)
methotrexate The salicylate increases the effect and toxicity of methotrexate (source: Drug Bank)
methotrexate Acetylsalicylic acid increases the effect and toxicity of methotrexate. (source: Drug Bank)
methylprednisolone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
methylprednisolone The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
paramethasone The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
prednisolone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
prednisolone The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
prednisone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
prednisone The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
probenecid The salicylate decreases the uricosuric effect of probenecid (source: Drug Bank)
probenecid Acetylsalicylic acid decreases the uricosuric effect of probenecid. (source: Drug Bank)
sulfinpyrazone The salicylate antagonizes the uricosuric effect of sulfinpyrazone (source: Drug Bank)
ticlopidine Increased effect of ticlopidine (source: Drug Bank)
ticlopidine Increased effect of ticlopidine (source: Drug Bank)
tolazamide Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide. (source: Drug Bank)
tolbutamide The salicylate increases the effect of sulfonylurea (source: Drug Bank)
tolbutamide Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide. (source: Drug Bank)
triamcinolone The corticosteroid decreases the effect of salicylates (source: Drug Bank)
triamcinolone The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank)
valproic acid The salicylate increases the effect of valproic acid (source: Drug Bank)
warfarin The salicylate increases the effect of anticoagulant (source: Drug Bank)
warfarin Acetylsalicylic acid increases the effect of the anticoagulant, warfarin. (source: Drug Bank)
aspirin The salicylate increases the effect of sulfonylurea (source: Drug Bank)
aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)
aspirin The salicylate increases the effect of sulfonylurea (source: Drug Bank)
aspirin The salicylate increases the effect of sulfonylurea (source: Drug Bank)
aspirin The salicylate increases the effect of sulfonylurea (source: Drug Bank)
aspirin Anticipate decrease of ASA efficiency in presence of griseofulvin (source: Drug Bank)
aspirin Association of ASA/Heparin increases risk of bleeding (source: Drug Bank)
aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)
aspirin Ibuprofen reduces ASA cardioprotective effects (source: Drug Bank)
aspirin The salicylate increases the effect of insulin (source: Drug Bank)
aspirin ASA increases toxicity of ketorolac (source: Drug Bank)
aspirin The salicylate at high dose increases the effect of the carbonic anhydrase inhibitors (source: Drug Bank)
aspirin The salicylate increases the effect and toxicity of methotrexate (source: Drug Bank)
aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)
aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)
aspirin The salicylate decreases the uricosuric effect of probenecid (source: Drug Bank)
aspirin Concomitant use of Telmisartan and Aspirin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
aspirin Concomitant use of Telmisartan and Aspirin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
aspirin Increased effect of ticlopidine (source: Drug Bank)
aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to aspirin: 132

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014. Tatarunas Vacis, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel. Platelets. 2014. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. American heart journal. 2014. Oestreich Julie H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of oral antiplatelet drugs. Pharmacogenomics. 2014. Yasmina Alfi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. Journal of thrombosis and thrombolysis. 2014. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thrombosis and haemostasis. 2013. Jeong Y-H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. Wang Jiping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Thrombosis research. 2013. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting. Scandinavian cardiovascular journal : SCJ. 2013. Wang Zanxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients. Clinica chimica acta; international journal of clinical chemistry. 2013. Luchessi André Ducati, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of tapasin polymorphisms with aspirin-exacerbated respiratory disease in asthmatics. Pharmacogenetics and genomics. 2013. Cho Sung-Hwan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. American heart journal. 2013. Gurbel Paul A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Variation in PEAR1 is Associated with Platelet Aggregation and Cardiovascular Outcomes. Circulation. Cardiovascular genetics. 2013. Lewis Joshua P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?. Heart (British Cardiac Society). 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC genomics. 2013. Daneshjou Roxana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine. 2012. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012. Uotani Takahiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. International journal of cardiology. 2012. Verschuren Jeffrey J W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis. Molecular and cellular biochemistry. 2012. Shuvalova Yu A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. British journal of clinical pharmacology. 2012. Kim In-Suk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. Pharmacogenetics and genomics. 2012. Liu Wen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart (British Cardiac Society). 2012. Oh Il-Young, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annual review of pharmacology and toxicology. 2012. Bharadwaj Mandvi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets. 2012. Marcucci Rossella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA : the journal of the American Medical Association. 2011. Cayla Guillaume, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of Toll-like Receptor 3 Variants in Aspirin-Exacerbated Respiratory Disease. Allergy, asthma & immunology research. 2011. Palikhe Nami Shrestha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart (British Cardiac Society). 2011. Park Kyung Woo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC. Cardiovascular interventions. 2011. Kim In-Suk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American heart journal. 2011. Gurbel Paul A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics. 2011. Oh Sun-Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical pharmacology and therapeutics. 2011. Maeda A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Digestive diseases and sciences. 2011. Shiotani Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma. Immunogenetics. 2011. Pasaje Charisse Flerida A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thrombosis research. 2011. Hwang Seok-Jae, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European heart journal. 2010. Harmsze Ankie M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenetics and genomics. 2010. Kim Byung Soo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Archives of internal medicine. 2010. Shehab Nadine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Current drug metabolism. 2010. Ancrenaz V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC. Cardiovascular interventions. 2010. Barker Colin M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. JAMA : the journal of the American Medical Association. 2010. Fuster Valentin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. American journal of epidemiology. 2010. Salinas Claudia A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug safety : an international journal of medical toxicology and drug experience. 2010. Youngster Ilan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population. Annals of human genetics. 2010. Pasaje Charisse Flerida A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The case for routine genotyping in dual-antiplatelet therapy. Journal of the American College of Cardiology. 2010. Damani Samir B, et al. PubMed
Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics. 2010. Kim Jin-Moo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. BMB reports. 2010. Park Byung-Lae, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thrombosis research. 2010. Abderrazek Fatma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert opinion on drug metabolism & toxicology. 2010. Giusti Betti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & therapeutics. 2010. Ma Terry K W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. Thrombosis and haemostasis. 2010. Montalescot Gilles, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Associations between polymorphisms in five inflammation-related genes and cognitive ability in older persons. Genes, brain, and behavior. 2010. Marioni R E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart (British Cardiac Society). 2010. Würtz Morten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2010. Tavassoli Neda, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2010. Pamukcu Burak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics. 2010. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Positive association between aspirin-intolerant asthma and genetic polymorphisms of FSIP1: a case-case study. BMC pulmonary medicine. 2010. Kim Jason Yongha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PloS one. 2010. Kim Jeong-Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association analysis of peroxisome proliferator-activated receptors gamma gene polymorphisms with asprin hypersensitivity in asthmatics. Allergy, asthma & immunology research. 2009. Oh Sun-Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Can we override clopidogrel resistance?. Circulation. 2009. Pena Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of antiplatelet drug resistance. Clinical genetics. 2009. Feher G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature reviews. Cardiology. 2009. Sweeny Joseph M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. The American journal of cardiology. 2009. Giusti Betti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. Translational research : the journal of laboratory and clinical medicine. 2009. Azam Salman M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thrombosis and haemostasis. 2009. Pettinella Caterina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respiratory medicine. 2009. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009. Kim S-H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between a TGFbeta1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. Journal of clinical pharmacy and therapeutics. 2008. Park H-J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. Journal of gastroenterology. 2009. Shiotani Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología. 2009. Sánchez-Borges M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. The New England journal of medicine. 2008. Burn John, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008. Kim T-H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arteriosclerosis, thrombosis, and vascular biology. 2008. Herrera-Galeano J Enrique, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respiratory medicine. 2008. Palikhe Nami Shrestha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis. 2008. Giusti Betti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European heart journal. 2008. Wallentin Lars, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clinical pharmacology and therapeutics. 2008. Lee C R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008. Cappellini M D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Analysis of high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients with aspirin-intolerant chronic urticaria. Allergy and asthma proceedings : the official journal of regional and state allergy societies. 2008. Palikhe Nami, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. The pharmacogenomics journal. 2007. Fujiwara T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Enhancing effect of the (145)Met-allele of GPIb alpha on platelet sensitivity to aspirin under high-shear conditions. Thrombosis research. 2008. Matsubara Yumiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics. 2007. Faraday Nauder, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007. Li Qing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007. Faraday Nauder, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007. Maree Andrew O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose-related efficacy of aspirin after coronary surgery in patients With Pl(A2) polymorphism (NCT00262275). The Annals of thoracic surgery. 2007. Lim Eric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aspirin and colon cancer--targeting prevention?. The New England journal of medicine. 2007. Markowitz Sanford D. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. The New England journal of medicine. 2007. Chan Andrew T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. The New England journal of medicine. 2007. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenetics and genomics. 2007. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of antiplatelet drugs. Current opinion in investigational drugs (London, England : 2000). 2007. Marín Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thrombosis research. 2007. Lev Eli I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thrombosis research. 2007. Cuisset Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thrombosis research. 2007. Dropinski Jerzy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology. 2006. Cooke Glen E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharmaceutical research. 2006. Lau Wei C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. The Journal of pharmacology and experimental therapeutics. 2006. Tang Man, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. The British journal of dermatology. 2006. Mastalerz L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thrombosis and haemostasis. 2006. Lepäntalo Aino, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclooxygenase-1 haplotype modulates platelet response to aspirin. Journal of thrombosis and haemostasis : JTH. 2005. Maree A O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. The Journal of thoracic and cardiovascular surgery. 2005. Morawski W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?. The Annals of pharmacotherapy. 2005. Papp Elod, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2005. Kim S-H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke; a journal of cerebral circulation. 2005. Ziegler Sophie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. The American journal of cardiology. 2005. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005. Ulrich Cornelia M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. Journal of the National Cancer Institute. 2005. Chan Andrew T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Aspirin resistance and a single gene. The American journal of cardiology. 2005. Jefferson Brian K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004. Lau Wei C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. The Journal of allergy and clinical immunology. 2004. Mastalerz Lucyna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003. Undas Anetta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. Journal of human genetics. 2003. Uno Yasuhiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001. Undas A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. British journal of haematology. 2000. Szczeklik A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000. Michelson A D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haemolytic potential of three chemotherapeutic agents and aspirin in glucose-6-phosphate dehydrogenase deficiency. Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ. 1999. Ali N A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet. 1999. Undas A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Therapeutic drug monitoring. 1998. Lennard L. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997. Walter D H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan. Annals of tropical paediatrics. 1990. Choudhry V P, et al. PubMed
Aspirin-induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase-deficient children with systemic arthritis. Acta haematologica. 1989. Meloni T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bulletin of the World Health Organization. 1989. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Aspirin-induced hemolysis: the role of concomitant oxidant (H2O2) challenge. Pediatric research. 1978. Stockman J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Evaluation of the hemolytic role of aspirin in glucose-6-phosphate dehydrogenase deficiency. The Journal of pediatrics. 1976. Glader B E. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Haemolytic jaundice following aspirin administration to a patient with a deficiency of glucose-6-phosphate dehydrogenase in erythrocytes. Acta haematologica. 1960. SZEINBERG A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Haemolytic jaundice following aspirin administration to a patient with a deficiency of glucose-6-phosphate dehydrogenase in erythrocytes. Acta haematologica. 1960. SZEINBERG A, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00945
PDB:
AIN
ChEBI:
15365
KEGG Compound:
C01405
KEGG Drug:
D00109
PubChem Compound:
2244
PubChem Substance:
4594
46505803
Drugs Product Database (DPD):
2237900
BindingDB:
22360
ChemSpider:
2157
HET:
AIN
Therapeutic Targets Database:
DAP000843

Clinical Trials

These are trials that mention aspirin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.